These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17263761)

  • 1. Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome.
    Kraemer de Aguiar LG; Laflor CM; Bahia L; Villela NR; Wiernsperger N; Bottino DA; Bouskela E
    Diabet Med; 2007 Mar; 24(3):272-9. PubMed ID: 17263761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
    de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
    Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
    Bouskela E; Kraemer de Aguiar LG; Nivoit P; Bahia LR; Villela NR; Bottino DA
    Bull Acad Natl Med; 2007 Mar; 191(3):475-92; discussion 492-3. PubMed ID: 18072649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
    Nieuwdorp M; Stroes ES; Kastelein JJ;
    Diabetes Obes Metab; 2007 Nov; 9(6):869-78. PubMed ID: 17924869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study.
    Jadhav S; Ferrell W; Greer IA; Petrie JR; Cobbe SM; Sattar N
    J Am Coll Cardiol; 2006 Sep; 48(5):956-63. PubMed ID: 16949486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of metformin in type 2 diabetes.
    Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
    Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
    Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.
    Fegan PG; Shore AC; Mawson D; Tooke JE; MacLeod KM
    Diabet Med; 2005 Dec; 22(12):1670-6. PubMed ID: 16401310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus.
    Carter AM; Bennett CE; Bostock JA; Grant PJ
    Diabet Med; 2005 Sep; 22(9):1282-4. PubMed ID: 16108864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.
    Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D
    In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study.
    Meigs JB; Larson MG; Fox CS; Keaney JF; Vasan RS; Benjamin EJ
    Diabetes Care; 2007 Oct; 30(10):2529-35. PubMed ID: 17586736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects.
    Formoso G; De Filippis EA; Michetti N; Di Fulvio P; Pandolfi A; Bucciarelli T; Ciabattoni G; Nicolucci A; Davì G; Consoli A
    Diabetes Metab Res Rev; 2008; 24(3):231-7. PubMed ID: 17966969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current indications for metformin therapy.
    Tankova T
    Rom J Intern Med; 2003; 41(3):215-25. PubMed ID: 15526505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nailfold videocapillaroscopy in primary Sjögren's syndrome.
    Aguiar T; Furtado E; Dorigo D; Bottino D; Bouskela E
    Angiology; 2006; 57(5):593-9. PubMed ID: 17067982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
    Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
    Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.